Nihat Kurt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nihat Kurt has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Heybet Kerem Polat
Republic of Turkey Ministry of Health, Turkish Medicines And Medical Devices Agency
5 shared publications - Eren Aytekin
Department of Pharmaceutical Technology, Faculty of Pharmacy Hacettepe University Ankara Türkiye
4 shared publications - Sibel Bozdağ Pehlivan
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara 06230, Turkey
4 shared publications - Nasıf Fatih Karakuyu
Department of Pharmacology, Faculty of Pharmacy, Süleyman Demirel University, Isparta, Turkey
3 shared publications - Sefa Gözcü
Erzincan Binali Yıldırım University, Faculty of Pharmacy, Department of Pharmacognosy, Erzincan, Türkiye
3 shared publications Behzat Tebrizi
2 shared publications
Latest Publications
- Open Access
- 2 August 2026
- Published by Wiley in Journal of the Science of Food and Agriculture
From nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients
Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences. By combining various polymers with active herbal ingredients, these systems mimic the natural extracellular matrix and provide improved functions such as a high surface area‐to‐volume ratio, drug targeting, and controlled drug release. Preclinical studies demonstrate that phytochemical‐containing nanofibers have improved therapeutic profiles, including higher anti‐inflammatory, antioxidant, antimicrobial, and antineoplastic effects. In various biomedical applications, such as promoting tissue engineering (such as bone and nerve regeneration), limiting tumor growth, and accelerating wound closure, it was shown that nanofibers may overcome the physicochemical limitations of herbal drugs such as low solubility and bioavailability. Despite promising preclinical study results, there are significant obstacles in the way of the commercialization of herbal drug‐loaded nanofibers. The difficult standardization of multi‐component herbal extracts, stabilization drawbacks, and the absence of scalable industrial manufacturing equipment that can maintain repeatable characterization of nanofibers are some of the major obstacles, in addition to a lack of clinical trials. To navigate the clinical translation of nanofibers, interdisciplinary collaboration regarding quality control, safety, and regulatory pathways is strictly necessary due to the case‐by‐case review approach utilized by regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This review offers a comprehensive overview of research on herbal drug‐loaded nanofibers and contributes a novel perspective with regulatory and clinical translational insights. © 2026 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- 2 August 2026
- Published by Wiley in Journal of the Science of Food and Agriculture
Open AccessFrom nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients
Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences. By combining various polymers with active herbal ingredients, these systems mimic the natural extracellular matrix and provide improved functions such as a high surface area‐to‐volume ratio, drug targeting, and controlled drug release. Preclinical studies demonstrate that phytochemical‐containing nanofibers have improved therapeutic profiles, including higher anti‐inflammatory, antioxidant, antimicrobial, and antineoplastic effects. In various biomedical applications, such as promoting tissue engineering (such as bone and nerve regeneration), limiting tumor growth, and accelerating wound closure, it was shown that nanofibers may overcome the physicochemical limitations of herbal drugs such as low solubility and bioavailability. Despite promising preclinical study results, there are significant obstacles in the way of the commercialization of herbal drug‐loaded nanofibers. The difficult standardization of multi‐component herbal extracts, stabilization drawbacks, and the absence of scalable industrial manufacturing equipment that can maintain repeatable characterization of nanofibers are some of the major obstacles, in addition to a lack of clinical trials. To navigate the clinical translation of nanofibers, interdisciplinary collaboration regarding quality control, safety, and regulatory pathways is strictly necessary due to the case‐by‐case review approach utilized by regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This review offers a comprehensive overview of research on herbal drug‐loaded nanofibers and contributes a novel perspective with regulatory and clinical translational insights. © 2026 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- 29 April 2026
- Published by Springer Nature in Bulletin of Materials Science
- Vol. 49 (2)
Silk-based drug delivery systems: Advances, challenges, and future perspectives
- 29 April 2026
- Published by Springer Nature in Bulletin of Materials Science
- Vol. 49 (2)
Silk-based drug delivery systems: Advances, challenges, and future perspectives
- Open Access
- 20 February 2026
- Published by Elsevier in SSRN Electronic Journal
From Extraction to Ocular Delivery: An Integrated Approach Using Apigenin and Apigenin 7-O-Glucoside Nanosuspensions to Treat Corneal Neovascularization
Corneal neovascularization (CNV) is a vision-threatening condition characterized by the pathological ingrowth of blood vessels. While corticosteroids and anti-VEGF agents are standard treatments, their prolonged use is associated with significant ocular side effects. This study aimed to develop and optimize nanosuspensions of Apigenin (APG) and Apigenin-7-O-glucoside (APG-7) to enhance their ocular bioavailability and evaluate their efficacy in the treatment of CNV. APG and APG-7 were isolated from Petroselinum crispum. Nanosuspensions were formulated using an anti-solvent precipitation method, optimized via a 23 factorial design considering PVA concentration, Span 80 concentration, and homogenization speed. The physicochemical properties, including particle size, PDI, and zeta potential, were characterized. In vivo efficacy was assessed in an alkali-burn induced rat CNV model through clinical scoring, histopathology, and immunohistochemical analysis of VEGFA and IL-6 expression. The optimized APG nanosuspensions exhibited a mean particle size of ~166.9 nm with high stability. In vivo studies demonstrated that 0.05% APG nanosuspension significantly inhibited corneal angiogenesis, reduced stromal edema, and downregulated VEGFA and IL-6 expression compared to the untreated injury group (p < 0.05). Conversely, APG-7 formulations failed to show significant therapeutic efficacy, likely due to limited corneal permeability attributed to the glycoside moiety. The 0.05% APG nanosuspension presents a promising, non-invasive therapeutic alternative for CNV management, offering effective anti-angiogenic activity with improved ocular delivery characteristics.
- 20 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFrom Extraction to Ocular Delivery: An Integrated Approach Using Apigenin and Apigenin 7-O-Glucoside Nanosuspensions to Treat Corneal Neovascularization
Corneal neovascularization (CNV) is a vision-threatening condition characterized by the pathological ingrowth of blood vessels. While corticosteroids and anti-VEGF agents are standard treatments, their prolonged use is associated with significant ocular side effects. This study aimed to develop and optimize nanosuspensions of Apigenin (APG) and Apigenin-7-O-glucoside (APG-7) to enhance their ocular bioavailability and evaluate their efficacy in the treatment of CNV. APG and APG-7 were isolated from Petroselinum crispum. Nanosuspensions were formulated using an anti-solvent precipitation method, optimized via a 23 factorial design considering PVA concentration, Span 80 concentration, and homogenization speed. The physicochemical properties, including particle size, PDI, and zeta potential, were characterized. In vivo efficacy was assessed in an alkali-burn induced rat CNV model through clinical scoring, histopathology, and immunohistochemical analysis of VEGFA and IL-6 expression. The optimized APG nanosuspensions exhibited a mean particle size of ~166.9 nm with high stability. In vivo studies demonstrated that 0.05% APG nanosuspension significantly inhibited corneal angiogenesis, reduced stromal edema, and downregulated VEGFA and IL-6 expression compared to the untreated injury group (p < 0.05). Conversely, APG-7 formulations failed to show significant therapeutic efficacy, likely due to limited corneal permeability attributed to the glycoside moiety. The 0.05% APG nanosuspension presents a promising, non-invasive therapeutic alternative for CNV management, offering effective anti-angiogenic activity with improved ocular delivery characteristics.
- Open Access
- 2 January 2024
- Published by Ankara Universitesi Eczacilik Fakultesi Dergisi in Ankara Universitesi Eczacilik Fakultesi Dergisi
- Vol. 48 (2) , 28
OKÜLER İLAÇ TAŞIYICI SİSTEM OLARAK LİPİT BAZLI NANOPARTİKÜLLER
Amaç: Bu derleme kapsamında, oküler kullanımdaki katı lipit nanopartikül (KLN) ve nanoyapılı lipit taşıyıcı (NLT) sistemlerine, bu formülasyonların sterilizasyonuna ve tasarımla kalite (QbD) hakkında yapılan son araştırmaları tartışmak amaçlanmıştır. Sonuç ve Tartışma: Göze ilaç taşınması son yıllardaki gelişmelere rağmen hala karmaşık bir sorun olarak devem etmekte ve etkili ilaç taşınabilmesi için yenilikçi yaklaşımlara ihtiyaç duyulan bir alandır. Bu derlemede, yenilikçi yaklaşımlardan olan KLN’ler ve NLT’lerin oftalmik ilaç uygulamalarında sağladıkları üstünlükler güncel literatür örnekleriyle tartışılmıştır. KLN’ler oda sıcaklığında katı halde bulunan lipitlerin genellikle eritilmesi ya da çeşitli solvanlarda çözündürülmesi ile hazırlanan lipit partiküllerdir. NLT’ler ise yapısında katı lipitlerle birlikte oda sıcaklığında sıvı halde bulunan lipitleri de içermektedir. Oküler ilaç uygulamalarında kritik aşamalardan biri de sterilizasyon basamağıdır. Uygun sterilizasyon işleminin seçiminde, kullanılan lipitlerin erime dereceleri, serbest radikal oluşturma eğilimleri ve partikül büyüklükleri göz önünde bulundurulmalıdır. Sonuç olarak, KLN ve NLT’ler hem biyouyumluluk hem de etkililik anlamında oküler tedaviler için umut vadeden ilaç taşıyıcı sistemlerdir. Derleme kapsamında incelenen literatür çalışmaları da bu çıkarımı desteklemektedir. Ancak saklama süresince karşılaşılabilen stabilite sorunları ve tekrarlanabilir büyük ölçekte üretim konusunda yaşanan sıkıntılar nedeniyle klinik tedavide yeterince kullanılamamaktadır. Bu sorunların çözümü aşamasında QbD’nin etkili olacağı düşünülmektedir.
- 2 January 2024
- Published by Ankara Universitesi Eczacilik Fakultesi Dergisi in Ankara Universitesi Eczacilik Fakultesi Dergisi
- Vol. 48 (2) , 28
Open AccessOKÜLER İLAÇ TAŞIYICI SİSTEM OLARAK LİPİT BAZLI NANOPARTİKÜLLER
Amaç: Bu derleme kapsamında, oküler kullanımdaki katı lipit nanopartikül (KLN) ve nanoyapılı lipit taşıyıcı (NLT) sistemlerine, bu formülasyonların sterilizasyonuna ve tasarımla kalite (QbD) hakkında yapılan son araştırmaları tartışmak amaçlanmıştır. Sonuç ve Tartışma: Göze ilaç taşınması son yıllardaki gelişmelere rağmen hala karmaşık bir sorun olarak devem etmekte ve etkili ilaç taşınabilmesi için yenilikçi yaklaşımlara ihtiyaç duyulan bir alandır. Bu derlemede, yenilikçi yaklaşımlardan olan KLN’ler ve NLT’lerin oftalmik ilaç uygulamalarında sağladıkları üstünlükler güncel literatür örnekleriyle tartışılmıştır. KLN’ler oda sıcaklığında katı halde bulunan lipitlerin genellikle eritilmesi ya da çeşitli solvanlarda çözündürülmesi ile hazırlanan lipit partiküllerdir. NLT’ler ise yapısında katı lipitlerle birlikte oda sıcaklığında sıvı halde bulunan lipitleri de içermektedir. Oküler ilaç uygulamalarında kritik aşamalardan biri de sterilizasyon basamağıdır. Uygun sterilizasyon işleminin seçiminde, kullanılan lipitlerin erime dereceleri, serbest radikal oluşturma eğilimleri ve partikül büyüklükleri göz önünde bulundurulmalıdır. Sonuç olarak, KLN ve NLT’ler hem biyouyumluluk hem de etkililik anlamında oküler tedaviler için umut vadeden ilaç taşıyıcı sistemlerdir. Derleme kapsamında incelenen literatür çalışmaları da bu çıkarımı desteklemektedir. Ancak saklama süresince karşılaşılabilen stabilite sorunları ve tekrarlanabilir büyük ölçekte üretim konusunda yaşanan sıkıntılar nedeniyle klinik tedavide yeterince kullanılamamaktadır. Bu sorunların çözümü aşamasında QbD’nin etkili olacağı düşünülmektedir.
- Open Access
- 21 December 2023
- Published by Hacettepe University in Hacettepe University Journal of the Faculty of Pharmacy
- Vol. 44 (2) , 182-197
Multipl Skleroz Tedavisinde Nanotaşıyıcı Sistemlerin Uygulanması
TürkçeNörodejeneratif hastalıklar arasında kompleks bir immünopatolojiye sahip olan Multipl Skleroz (MS)’un tedavisinde birçok faktörün dikkate alınması gerekmektedir. Bu çok faktörlü hastalıktaki klinik bulgular miyelin kaybının ilerlemesine, enflamasyonun evresine, aksonların durumuna ve oligodendrosit öncü hücrelerinin aktivitesine bağlıdır. Uzun yıllardır süregelen yoğun çalışmalara rağmen hastalığın çok faktörlü oluşu ve kan-beyin engeli (KBE) gibi ilaçların beyne ulaşmasını engelleyen yapılar nedeniyle henüz kesin bir tedavi bulunamamıştır. Bu durum, bilim insanlarını yeni yaklaşımlar aramaya yönlendirmiştir. Yapılan araştırmalarda genellikle nanotaşıyıcı olarak adlandırılan nano boyuttaki farmasötik taşıyıcıların MS’nin yalnızca teşhisinde değil aynı zamanda tedavisinde de rol üstlenebileceğini göstermiştir. MS’nin tedavisi için klinik öncesi in vitro ve in vivo çalışmalarla başarılı olduğu gösterilen bu sistemlerin klinik uygulamaya geçiş yapabilmesi için çalışmalar yoğun bir şekilde devam etmektedir. Bu derlemede MS tedavisine yönelik nanotaşıyıcılar konusunda literatürde yer alan en güncel gelişmeler değerlendirilmiştir.
- 21 December 2023
- Published by Hacettepe University in Hacettepe University Journal of the Faculty of Pharmacy
- Vol. 44 (2) , 182-197
Open AccessMultipl Skleroz Tedavisinde Nanotaşıyıcı Sistemlerin Uygulanması
TürkçeNörodejeneratif hastalıklar arasında kompleks bir immünopatolojiye sahip olan Multipl Skleroz (MS)’un tedavisinde birçok faktörün dikkate alınması gerekmektedir. Bu çok faktörlü hastalıktaki klinik bulgular miyelin kaybının ilerlemesine, enflamasyonun evresine, aksonların durumuna ve oligodendrosit öncü hücrelerinin aktivitesine bağlıdır. Uzun yıllardır süregelen yoğun çalışmalara rağmen hastalığın çok faktörlü oluşu ve kan-beyin engeli (KBE) gibi ilaçların beyne ulaşmasını engelleyen yapılar nedeniyle henüz kesin bir tedavi bulunamamıştır. Bu durum, bilim insanlarını yeni yaklaşımlar aramaya yönlendirmiştir. Yapılan araştırmalarda genellikle nanotaşıyıcı olarak adlandırılan nano boyuttaki farmasötik taşıyıcıların MS’nin yalnızca teşhisinde değil aynı zamanda tedavisinde de rol üstlenebileceğini göstermiştir. MS’nin tedavisi için klinik öncesi in vitro ve in vivo çalışmalarla başarılı olduğu gösterilen bu sistemlerin klinik uygulamaya geçiş yapabilmesi için çalışmalar yoğun bir şekilde devam etmektedir. Bu derlemede MS tedavisine yönelik nanotaşıyıcılar konusunda literatürde yer alan en güncel gelişmeler değerlendirilmiştir.
- 7 April 2023
- Published by Academician Publishing
- p. 153-172
Kuru Göz Tedavisi İçin İlaç Taşıyıcı Sistemler
- 7 April 2023
- Published by Academician Publishing
- p. 153-172
Kuru Göz Tedavisi İçin İlaç Taşıyıcı Sistemler
- 28 June 2022
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 38 (6) , 376-395
Novel Drug Delivery Systems to Improve the Treatment of Keratitis
Keratitis is a disease characterized by inflammation of the cornea caused by different pathogens. It can cause serious visual morbidity if not treated quickly. Depending on the pathogen causing keratitis, eye drops containing antibacterial, antifungal, or antiviral agents such as besiloxacin, moxifloxacin, ofloxacin, voriconazol, econazole, fluconazole, and acyclovir are used, and these drops need to be applied frequently due to their low bioavailability. Studies are carried out on formulations with extended residence time in the cornea and increased permeability. These formulations include various new drug delivery systems such as inserts, nanoparticles, liposomes, niosomes, cubosomes, microemulsions, in situ gels, contact lenses, nanostructured lipid carriers, carbon quantum dots, and microneedles. Ex vivo and in vivo studies with these formulations have shown that the residence time of the active substances in the cornea is prolonged, and their ocular bioavailability is increased. In addition, in vivo studies have shown that these formulations successfully treat keratitis. However, it has been observed that fluoroquinolones are used in most of the studies; similar drug delivery systems are generally preferred for antifungal drugs, and studies for viral and acanthameba keratitis are limited. There is a need for new studies on different types of keratitis and different drug active substances. At the same time, proving the efficacy of drug delivery systems, which give promising results in in vivo animal models, with clinical studies is of great importance for progress in the treatment of keratitis.
- 28 June 2022
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 38 (6) , 376-395
Novel Drug Delivery Systems to Improve the Treatment of Keratitis
Keratitis is a disease characterized by inflammation of the cornea caused by different pathogens. It can cause serious visual morbidity if not treated quickly. Depending on the pathogen causing keratitis, eye drops containing antibacterial, antifungal, or antiviral agents such as besiloxacin, moxifloxacin, ofloxacin, voriconazol, econazole, fluconazole, and acyclovir are used, and these drops need to be applied frequently due to their low bioavailability. Studies are carried out on formulations with extended residence time in the cornea and increased permeability. These formulations include various new drug delivery systems such as inserts, nanoparticles, liposomes, niosomes, cubosomes, microemulsions, in situ gels, contact lenses, nanostructured lipid carriers, carbon quantum dots, and microneedles. Ex vivo and in vivo studies with these formulations have shown that the residence time of the active substances in the cornea is prolonged, and their ocular bioavailability is increased. In addition, in vivo studies have shown that these formulations successfully treat keratitis. However, it has been observed that fluoroquinolones are used in most of the studies; similar drug delivery systems are generally preferred for antifungal drugs, and studies for viral and acanthameba keratitis are limited. There is a need for new studies on different types of keratitis and different drug active substances. At the same time, proving the efficacy of drug delivery systems, which give promising results in in vivo animal models, with clinical studies is of great importance for progress in the treatment of keratitis.
- 8 June 2022
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 38 (6) , 412-423
Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers: In Vitro and Ex Vivo Evaluation
Objective: In the treatment of severe cases of bacterial keratitis, conventional eye drops containing antibiotics should be applied daily and very frequently. The aim of this study is to develop low-dose high-effect formulations with the prepared nanostructured lipid carrier (NLC) formulations to reduce antibiotic resistance and increase patient compliance. Methods: NLC formulations were loaded with besifloxacin HCl (BHL) and the besifloxacin HCl: sulfobutyl ether beta-cyclodextrin (SBE-CD) complex. Positive charge was gained with chitosan, and corneal permeation and resolubility were increased with SBE-CD. In vitro characterization studies, permeability studies, and cytotoxicity and ex vivo transport studies were carried out. Results: In this study, it was found that SBE-CD increased BHL's solubility by 8-fold based on phase solubility studies. The optimized NLCs were small in size (13.63–16.09 nm) with a low polydispersity index (0.107–0.181) and adequate BHL drug loading efficiency. In vitro release studies showed that formulations were released approximately for 8 h and at levels over the minimum inhibitory concentration of Pseudomonas aeruginosa and Staphylococcus aureus . NLC formulations had a better corneal permeation rate than the marketed product during 6 h of ex vivo studies. Conclusions: According to in vitro and ex vivo data, it was determined that the most favorable NLC formulation was the formulation containing BHL/SBE-CD that was covered with chitosan. It has the highest drug loading capacity and one of the highest ex vivo corneal passage levels, along with desired drug release. The formulation containing BHL/SBE-CD and chitosan can be a potential alternative for the treatment of bacterial keratitis.
- 8 June 2022
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 38 (6) , 412-423
Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers: In Vitro and Ex Vivo Evaluation
Objective: In the treatment of severe cases of bacterial keratitis, conventional eye drops containing antibiotics should be applied daily and very frequently. The aim of this study is to develop low-dose high-effect formulations with the prepared nanostructured lipid carrier (NLC) formulations to reduce antibiotic resistance and increase patient compliance. Methods: NLC formulations were loaded with besifloxacin HCl (BHL) and the besifloxacin HCl: sulfobutyl ether beta-cyclodextrin (SBE-CD) complex. Positive charge was gained with chitosan, and corneal permeation and resolubility were increased with SBE-CD. In vitro characterization studies, permeability studies, and cytotoxicity and ex vivo transport studies were carried out. Results: In this study, it was found that SBE-CD increased BHL's solubility by 8-fold based on phase solubility studies. The optimized NLCs were small in size (13.63–16.09 nm) with a low polydispersity index (0.107–0.181) and adequate BHL drug loading efficiency. In vitro release studies showed that formulations were released approximately for 8 h and at levels over the minimum inhibitory concentration of Pseudomonas aeruginosa and Staphylococcus aureus . NLC formulations had a better corneal permeation rate than the marketed product during 6 h of ex vivo studies. Conclusions: According to in vitro and ex vivo data, it was determined that the most favorable NLC formulation was the formulation containing BHL/SBE-CD that was covered with chitosan. It has the highest drug loading capacity and one of the highest ex vivo corneal passage levels, along with desired drug release. The formulation containing BHL/SBE-CD and chitosan can be a potential alternative for the treatment of bacterial keratitis.